Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and CPT-11 in Recurrent Malignant Gliomas
NCT00412542Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2003
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and irinotecan in glioblastoma multiforme (GBM) and anaplastic glioma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 6 Months. Started Oct 2003; status: completed.
02
Drugs
thalidomideirinotecan
03
Conditions
glioblastoma multiforme (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT00412542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412542.